Sino Biopharmaceutical Limited (OTCMKTS:SBMFF - Get Free Report) shares hit a new 52-week high during trading on Tuesday . The company traded as high as $0.49 and last traded at $0.49, with a volume of 690 shares traded. The stock had previously closed at $0.47.
Sino Biopharmaceutical Stock Performance
The company has a 50 day simple moving average of $0.44 and a two-hundred day simple moving average of $0.43. The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.07 and a current ratio of 1.15.
Sino Biopharmaceutical Company Profile
(
Get Free Report)
Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company offers oncology medicines, including anlotinib hydrochloride capsules under Focus V brand, penpulimab injection under Annike brand, efbemalenograstin alfa injection under Yilishu brand, pomalidomide capsules under Anyue brand, bevacizumab injection under Anbeisi brand, rituximab injection under Delituo brand, and trastuzumab for injection under Saituo brand; liver disease medications, such as magnesium isoglycyrrhizinate injection under Tianqing Ganmei brand and entecavir dispersible tablets under Runzhong brand; and respiratory system medicines comprising budesonide suspension for inhalation under Tianqing suchang brand and colistimethate sodium for injection under Tianyun brand.
Further Reading
Before you consider Sino Biopharmaceutical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sino Biopharmaceutical wasn't on the list.
While Sino Biopharmaceutical currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
